Serengeti Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Serengeti Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,000	Closed	-$1.51M	–	52
2021 Q3	$1.51M	Buy	+15,000	New	+$1.76M	0.05%	20
2021 Q2	–	Sell	-25,000	Closed	-$2.49M	–	63
2021 Q1	$2.49M	Hold	25,000	–	–	1.09%	6
2020 Q4	$3.09M	Sell	25,000 -3,000	-11%	-$394K	1.01%	7
2020 Q3	$2.73M	Buy	28,000 +23,000	+460%	+$2.87M	0.85%	9
2020 Q2	$780K	Sell	5,000 -10,000	-67%	-$1.52M	0.27%	12
2020 Q1	$2.17M	Buy	+15,000	New	+$2.9M	2.25%	10

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Serengeti Asset Management's RETA Position: Q4 2021 in Review

Serengeti Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 15,000 shares — an estimated $1.51M sold.

Serengeti Asset Management first reported a position in RETA in Q1 2020 and held it in 6 quarters. The position peaked at $3.09M in Q4 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

Serengeti Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Serengeti Asset Management sold 15,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $1.51M.
Serengeti Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 6 quarters.
Serengeti Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.09M in Q4 2020.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Serengeti Asset Management's 13F filing for Q4 2021, filed 15 Feb 2022.